[
  {
    "ts": null,
    "headline": "Moderna Stock on the Move: What Sparked the 13% Jump in the Past Week?",
    "summary": "MRNA shares rise after upbeat 2025 sales, stronger cash outlook and detailed 2026 guidance, alongside multiple pipeline milestones.",
    "url": "https://finnhub.io/api/news?id=b34c518ef8909d1717e6f872ca1def1b4e9f0216e87cf4e1eb1abd9511e2202a",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1768485180,
      "headline": "Moderna Stock on the Move: What Sparked the 13% Jump in the Past Week?",
      "id": 138121622,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "MRK",
      "source": "Yahoo",
      "summary": "MRNA shares rise after upbeat 2025 sales, stronger cash outlook and detailed 2026 guidance, alongside multiple pipeline milestones.",
      "url": "https://finnhub.io/api/news?id=b34c518ef8909d1717e6f872ca1def1b4e9f0216e87cf4e1eb1abd9511e2202a"
    }
  },
  {
    "ts": null,
    "headline": "Why Merck's 32% Rally Isn't Enough to Change the Bearish View",
    "summary": "MRK is up over 32% in three months, but declining estimates, Keytruda's upcoming LOE and Gardasil declines keep the stock sell-rated.",
    "url": "https://finnhub.io/api/news?id=458b17ff156cdfe3bf97831959ed2ab8d4490169bf9393125aa0601d3ffaadc5",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1768483560,
      "headline": "Why Merck's 32% Rally Isn't Enough to Change the Bearish View",
      "id": 138121561,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "MRK",
      "source": "Yahoo",
      "summary": "MRK is up over 32% in three months, but declining estimates, Keytruda's upcoming LOE and Gardasil declines keep the stock sell-rated.",
      "url": "https://finnhub.io/api/news?id=458b17ff156cdfe3bf97831959ed2ab8d4490169bf9393125aa0601d3ffaadc5"
    }
  }
]